Ocuphire Pharma to Present at Two Investor Conferences in August
Ocuphire Pharma (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company, has announced its participation in two upcoming investor conferences. Dr. George Magrath, the company's CEO, will present at:
1. The Canaccord Genuity 44th Annual Growth Conference in Boston, MA on August 14, 2024 at 9:00 a.m. ET in a fireside chat format.
2. The H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024 at 10:30 a.m. ET, delivering a presentation.
Ocuphire Pharma focuses on developing small-molecule therapies for retinal and refractive eye disorders. Company management will be available for one-on-one meetings during both conferences. Interested parties can contact their conference representative or email ir@ocuphire.com to arrange meetings.
Ocuphire Pharma (Nasdaq: OCUP), un'azienda biofarmaceutica oftalmica in fase clinica, ha annunciato la sua partecipazione a due prossimi conferenze per investitori. Il Dr. George Magrath, CEO dell'azienda, presenterà a:
1. La 44a Conferenza Annuale sulla Crescita di Canaccord Genuity a Boston, MA il 14 agosto 2024 alle 9:00 ET in formato di conversazione informale.
2. La 4a Conferenza Virtuale Annuale di Oftalmologia H.C. Wainwright il 15 agosto 2024 alle 10:30 ET, con una presentazione.
Ocuphire Pharma si concentra sullo sviluppo di terapie a piccole molecole per disturbi retinici e ametropie. La direzione dell'azienda sarà disponibile per incontri individuali durante entrambe le conferenze. Le parti interessate possono contattare il loro rappresentante alla conferenza o inviare un'email a ir@ocuphire.com per organizzare incontri.
Ocuphire Pharma (Nasdaq: OCUP), una empresa biofarmacéutica oftálmica en etapa clínica, ha anunciado su participación en dos próximas conferencias para inversionistas. El Dr. George Magrath, CEO de la empresa, presentará en:
1. La 44ª Conferencia Anual de Crecimiento de Canaccord Genuity en Boston, MA el 14 de agosto de 2024 a las 9:00 a.m. ET en un formato de charla informal.
2. La 4ª Conferencia Virtual Anual de Oftalmología H.C. Wainwright el 15 de agosto de 2024 a las 10:30 a.m. ET, haciendo una presentación.
Ocuphire Pharma se centra en desarrollar terapias de pequeñas moléculas para trastornos retinianos y refractivos. La dirección de la empresa estará disponible para reuniones individuales durante ambas conferencias. Las partes interesadas pueden contactar a su representante de conferencia o enviar un correo electrónico a ir@ocuphire.com para organizar reuniones.
Ocuphire Pharma (Nasdaq: OCUP), 임상 단계의 안과 생물 의약품 회사가 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다. Dr. George Magrath CEO가 다음과 같은 회의에서 발표할 예정입니다:
1. Canaccord Genuity 제44회 연례 성장 컨퍼런스가 2024년 8월 14일 오전 9시(동부 표준시) 보스턴에서 fireside chat 형식으로 진행됩니다.
2. H.C. Wainwright 제4회 연례 안과 가상 컨퍼런스가 2024년 8월 15일 오전 10시 30분(동부 표준시)에 발표를 진행합니다.
Ocuphire Pharma는 망막 및 굴절 이상 치료를 위한 소분자 요법 개발에 중점을 두고 있습니다. 회사 경영진은 두 회의 동안 일대일 미팅을 진행할 수 있습니다. 관심 있는 분들은 회의 담당자에게 연락하거나 ir@ocuphire.com으로 이메일을 보내 미팅을 조율하시기 바랍니다.
Ocuphire Pharma (Nasdaq: OCUP), une société biomédicale en ophtalmologie en phase clinique, a annoncé sa participation à deux prochaines conférences pour investisseurs. Dr George Magrath, le PDG de l'entreprise, présentera lors de :
1. La 44e Conférence Annuelle de Croissance de Canaccord Genuity à Boston, MA, le 14 août 2024 à 9h00 ET sous forme de discussion informelle.
2. La 4e Conférence Virtuelle Annuelle en Ophtalmologie de H.C. Wainwright le 15 août 2024 à 10h30 ET, avec une présentation.
Ocuphire Pharma se concentre sur le développement de thérapies à petites molécules pour les troubles rétiniens et réfractifs. La direction de l'entreprise sera disponible pour des réunions en tête-à-tête lors des deux conférences. Les parties intéressées peuvent contacter leur représentant de conférence ou envoyer un courriel à ir@ocuphire.com pour organiser des réunions.
Ocuphire Pharma (Nasdaq: OCUP), ein biopharmazeutisches Unternehmen im Bereich Augenheilkunde in der klinischen Phase, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Dr. George Magrath, der CEO des Unternehmens, wird bei folgenden Konferenzen präsentieren:
1. Auf der 44. Jahrestagung von Canaccord Genuity in Boston, MA am 14. August 2024 um 9:00 Uhr ET im Rahmen eines informellen Gesprächs.
2. Auf der 4. Virtuellen Jahrestagung für Augenheilkunde von H.C. Wainwright am 15. August 2024 um 10:30 Uhr ET mit einer Präsentation.
Ocuphire Pharma konzentriert sich auf die Entwicklung von kleinen Molekülen für Netzhaut- und Refraktionsstörungen. Das Unternehmensmanagement steht während beider Konferenzen für Einzelgespräche zur Verfügung. Interessierte können sich an ihren Konferenzvertreter wenden oder eine E-Mail an ir@ocuphire.com senden, um Meetings zu vereinbaren.
- None.
- None.
FARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that George Magrath, M.D., M.B.A., M.S., Chief Executive Officer, will present at the Canaccord Genuity 44th Annual Growth Conference, to take place in Boston, MA, August 14, 2024, and at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, to take place virtually, on August 15, 2024.
| Event: | Canaccord Genuity 44th Annual Growth Conference |
| Location: | Boston, MA |
| Presenter: | Dr. George Magrath |
| Date: | August 14, 2024 |
| Time: | 9:00 a.m. ET |
| Format: | Fireside Chat |
| Event: | H.C. Wainwright 4th Annual Ophthalmology Virtual Conference |
| Location: | Virtual |
| Presenter: | Dr. George Magrath |
| Date: | August 15, 2024 |
| Time: | 10:30 a.m. ET |
| Format: | Presentation |
Company management will also be available for one-on-one meetings throughout the conferences. If you are interested in arranging a meeting, please contact your conference representative or send an email to ir@ocuphire.com.
About Ocuphire Pharma
Ocuphire Pharma, Inc. (Nasdaq: OCUP) is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of patients with retinal and refractive eye disorders. Ocuphire’s lead product candidate, APX3330, a novel small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein), is in development for diabetic retinopathy. In addition, Ocuphire’s late-stage product candidate Phentolamine Ophthalmic Solution
Contacts
| Corporate | Investor Relations |
| Nirav Jhaveri, M.B.A. CFO ir@ocuphire.com | Corey Davis, Ph.D. LifeSci Advisors cdavis@lifesciadvisors.com |
FAQ
When and where will Ocuphire Pharma (OCUP) present at the Canaccord Genuity conference?
What is the format of Ocuphire Pharma's (OCUP) presentation at the Canaccord Genuity conference?
When is Ocuphire Pharma (OCUP) scheduled to present at the H.C. Wainwright conference?
Who will be presenting on behalf of Ocuphire Pharma (OCUP) at these investor conferences?
How can investors arrange meetings with Ocuphire Pharma (OCUP) management during these conferences?
